Headaches are a common adverse effect of fluoxetine therapy. A patient who developed vascular headaches while being treated for depression is reported and possible mechanisms discussed.
Headache is described as a frequent adverse effect of fluoxetine, occurring in about 20% of patients receiving the drug (Wernicke, 1985) . The occurrence of headaches during therapy is also a common theme in patients receiving other selective serotonin reuptake blockers (SSRIs) (Rickels & Schweizer, 1990) . What is, however, not clear from literature is the type of headaches that develop -consider, for example, that in clinical practice, the commonest types of headaches encountered are tension headache and vascular headaches. A case report is hence presented here to describe the association of vascular headaches with fluoxetine therapy.
CASE REPORT
Ms. M, 27, presented with a 4 month history of depression, weeping spells, decreased libido, insomnia with early morning awakening, decreased appetite, loss of weight and psychomotor retardation. She fulfilled DSM III-R criteria for Major Depression with melancholia. She was started on fluoxetine, 20 mg each morning. By the end of two weeks she reported slight improvement in the severity of her depression. She continued to improve steadily and, after the second month of therapy, achieved remission from all symptoms. Fluoxetine was continued for 6 months further and was then tapered off and discontinued.
Within the second week of therapy itself she began to report a new symptom -headaches. With progress of fluoxetine therapy, the headaches increased in frequency, duration and severity. The headaches occurred four to five times a week and were characteristically bilateral and throbbing in nature. There was associated nausea and intolerance to light, but no preceding aura or warning of any sort. There was no history of such headaches at any time in the past.
The headaches, clearly vascular in origin, were treated with propranolol in the dose of 20 mg twice daily. Propranolol was stepped up over two weeks to 40 mg thrice a day. At this dose, headaches decreased in frequency to about once a fortnight. Propranolol was continued for the duration of fluoxetine therapy and was tapered off and withdrawn along with the fluoxetine. One year later, the patient remains free from both depression and vascular headaches. She requires no medication for either complaint.
DISCUSSION
The SSRIs facilitate serotonergic neurotransmission. Enhanced serotonergicity has been suggested as one explanation for vascular headaches (Raskin, 1988) . This may explain the association between vascular headaches and fluoxetine therapy as observed in the case above. Curiously, fluoxetine has also been used in the prophylaxis of migraine (Raskin, 1988) . Until the aetiology of vascular headaches and the role of serotonergic neurotransmission therein is better understood, it is futile to speculate on the possible mechanisms of balance that fluoxetine maintains or disturbs in preventing or precipitating headaches; however, the possibility of such an adverse effect of SSRIs must hence be kept in mind, particularly when treating a patient with a prior history of vascular headaches.
